Actively Recruiting
Study of Pegcetacoplan Combined with Modified FOLFIRINOX Chemotherapy to Treat Metastatic Pancreatic Ductal Adenocarcinoma
Led by Roswell Park Cancer Institute · Updated on 2026-08-19
35
Participants Needed
1
Research Sites
32 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating pegcetacoplan combined with a chemotherapy regimen called modified FOLFIRINOX for treating patients with metastatic pancreatic ductal adenocarcinoma PDAC, a type of pancreatic cancer that has spread to other parts of the body. This phase III study aims to assess the safety, tolerability, and preliminary effectiveness of this combination treatment. Additionally, the trial investigates whether pegcetacoplan can reduce the occurrence of major blood clots and related complications, which are common and potentially life-threatening in PDAC patients. Participants receive pegcetacoplan intravenously at the start of treatment and then self-administer it under the skin three times a week, or receive it intravenously before chemotherapy on office visit days. Chemotherapy drugs oxaliplatin, irinotecan, leucovorin, and fluorouracil are given intravenously in cycles every two weeks for up to eight cycles, unless disease progression or unacceptable side effects occur. Throughout the study, patients may undergo imaging scans like CT or MRI, tumor biopsies, and fluid or blood sample collections to monitor treatment effects and disease status. During the trial, participants will be closely monitored for treatment-related side effects and disease progression. Follow-up visits will occur 30 days after treatment ends, then every three months for up to three years. The study measures include the incidence of adverse events, progression-free survival, overall response rates, overall survival, disease control rates, and the occurrence of major blood clot events. Biomarkers from blood and tissue samples will also be studied to understand the therapys effects on the immune system and tumor environment.
CONDITIONS
Brief Title
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Research Team
S
Sarah Chatley, BS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here